Mark C. McKenna - 20 May 2022 Form 4 Insider Report for Prometheus Biosciences, Inc.

Role
Chairman, President & CEO, Director
Signature
Timothy K. Andrews, attorney-in-fact for Mark C. McKenna
Issuer symbol
N/A
Transactions as of
20 May 2022
Net transactions value
$0
Form type
4
Filing time
20 May 2022, 19:11:49 UTC
Previous filing
03 Dec 2021
Next filing
13 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXDX Stock Option (Right to Buy) Award $0 +246,639 $0.000000 246,639 20 May 2022 Common Stock 246,639 $29.56 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest in full on the third anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.